CoChat

Effect of Antidepressant Medication Treatment on Suicidal Ideation and Behavior in a Randomized Trial: An Exploratory Report From the Combining Medications to Enhance Depression Outcomes Study

The DOI matches its Crossref record.

Abstract

OBJECTIVE: To explore relationships between baseline sociodemographic and clinical features and baseline suicidal ideation, and treatment effects on suicidal ideation and behavior, in depressed outpatients. METHOD: From March 2008 to September 2009, the Combining Medications to Enhance Depression Outcomes study, a single-blind, 7-month randomized trial, enrolled outpatients with nonpsychotic chronic and/or recurrent major depressive disorder (DSM-IV-TR criteria) in primary and psychiatric care (N = 665). Participants received escitalopram plus placebo, bupropion sustained release (SR) plus escitalopram, or venlafaxine extended release (XR) plus mirtazapine. The primary outcome measure for this report is presence of suicidal ideation assessed by the Concise Health Risk Tracking Self-Report, which measures suicidal ideation and behaviors over the last 24 hours. Sociodemographic and clinical features were compared in those with versus without baseline ideation. At 4, 12, and 28 weeks, treatment effects on suicidality were assessed, and unadjusted and adjusted outcomes were compared among those with and without baseline ideation using linear, logistic, ordinal logistic, and negative binomial regression models. RESULTS: Baseline suicidal ideation was associated with greater depressive severity, childhood neglect, childhood abuse, early major depressive disorder onset, greater psychiatric comorbidity, and worse functioning and quality of life. After adjustment for treatment, gender, age at first depressive episode, obsessive-compulsive symptoms, and depressive severity, depressive symptom outcomes did not differ between ideation groups at 12 or 28 weeks or between treatments. Overall, 79% of participants with baseline suicidal ideation had none at week 4, 83% had none at week 12, and 86% had none at week 28. All treatments reduced ideation, with bupropion-SR plus escitalopram the most effective at week 12 (P < .01). In participants without baseline ideation, emergent ideation did not differ between treatments: 2.5% had ideation at 4 weeks, 1.3% had ideation at 12 weeks, and only 1.7% had ideation at 28 weeks. Four patients (all receiving venlafaxine-XR plus mirtazapine) attempted suicide (P = .0162). CONCLUSION: Baseline ideation did not affect depressive symptom outcome. Bupropion-SR plus escitalopram most effectively reduced ideation. Ideation emergence was uncommon. Venlafaxine-XR plus mirtazapine may pose a higher risk of suicide attempts. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00590863.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.10m06724

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 55

Metadata

Authors
Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., Nierenberg, A. A., Fava, M., Luther, J. F., Morris, D. W., & Trivedi, M. H.
Affiliations
  • University of California San Diego (US)
  • University of California, Los Angeles (US)
  • National University of Singapore (SG)
  • University of Pittsburgh (US)
  • Harvard University (US)
Corresponding author
Zisook, Sidney
Venue
The Journal of Clinical Psychiatry
Published
2011-10-15
Volume
72
Issue
10
Pages
1322-1332
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2094303122
Cited by
55
References
0
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 7 · 2012: 4
FWCI
4.48
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
Funders
  • National Institutes of Health (n01mh90003-26-0-0)
  • National Institute of Mental Health (N01‐MH‐90003)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
suicidal ideation, suicidal behavior, major depressive disorder, antidepressant treatment, escitalopram, bupropion, venlafaxine, mirtazapine, child neglect, childhood abuse, depression severity, suicide attempts, treatment response, psychiatric comorbidity, quality of life, primary care depression treatment
MeSH terms
Venlafaxine Hydrochloride, Mirtazapine, Adolescent, Adult, Aged, Antidepressive Agents, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Mianserin, Middle Aged, Surveys and Questionnaires, Regression Analysis, Risk Factors, Time Factors, Citalopram, Single-Blind Method, Bupropion, Treatment Outcome, Young Adult, Self Report, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Antidepressant Medication Treatment on Suicidal Ideation and Behavior in a Randomized Trial: An Exploratory Report From the Combining Medications to Enhance Depression Outcomes Study. https://app.cochat.ai/papers/10.4088/jcp.10m06724
The paper
Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., Nierenberg, A. A., Fava, M., Luther, J. F., Morris, D. W., & Trivedi, M. H. (2011). Effect of Antidepressant Medication Treatment on Suicidal Ideation and Behavior in a Randomized Trial: An Exploratory Report From the Combining Medications to Enhance Depression Outcomes Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.10m06724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.